

Research article

## Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination

William Soumbe Alley<sup>1</sup>, Gerrit GJ van oortmarsen<sup>2</sup>, Boakye BA Boatin<sup>1</sup>, Nico NJD Nagelkerke<sup>\*2</sup>, Anton Ap Plaisier<sup>2</sup>, Hans J Remme<sup>3</sup>, Janis Lazdins<sup>3</sup>, Gerard JJM Borsboom<sup>2</sup> and J Dik F Habbema<sup>2</sup>

Address: <sup>1</sup>Onchocerciasis Control Programme, World Health Organization, B.P. 549, Ouagadougou, Burkina Faso, <sup>2</sup>Department of Public Health, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands and <sup>3</sup>World Health Organization, Geneva 27, Switzerland

E-mail: William Soumbe Alley - EdohS@whoafr.org; Gerrit GJ van oortmarsen - Vanoortmarsen@mgz.fgg.eur.nl; Boakye BA Boatin - Boatin@oncho.oms.bf; Nico NJD Nagelkerke\* - Nagelkerke@mgz.fgg.eur.nl; Anton Ap Plaisier - aplaisier@baan.com; Hans J Remme - remmej@who.ch; Janis Lazdins - Lazdins@who.ch; Gerard JJM Borsboom - borsboom@mgz.fgg.eur.nl; J Dik F Habbema - habbema@mgz.fgg.eur.nl

\*Corresponding author

Published: 6 November 2001

Received: 14 August 2001

BMC Public Health 2001, 1:12

Accepted: 6 November 2001

This article is available from: <http://www.biomedcentral.com/1471-2458/1/12>

© 2001 Alley et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [info@biomedcentral.com](mailto:info@biomedcentral.com)

### Abstract

**Background:** In most endemic parts of the world, onchocerciasis (river blindness) control relies, or will soon rely, exclusively on mass treatment with the microfilaricide ivermectin. Worldwide eradication of the parasite by means of this drug is unlikely. Macrofilaricidal drugs are currently being developed for human use.

**Methods:** We used ONCHOSIM, a microsimulation mathematical model of the dynamics of onchocerciasis transmission, to explore the potentials of a hypothetical macrofilaricidal drug for the elimination of onchocerciasis under different epidemiological conditions, as characterized by previous intervention strategies, vectorial capacity and levels of coverage.

**Results:** With a high vector biting rate and poor coverage, a very effective macrofilaricide would appear to have a substantially higher potential for achieving elimination of the parasite than does ivermectin.

**Conclusions:** Macrofilaricides have a substantially higher potential for achieving onchocerciasis elimination than ivermectin, but high coverage levels are still key. When these drugs become available, onchocerciasis elimination strategies should be reconsidered. In view of the impact of control efforts preceding the introduction of macrofilaricides on the success of elimination, it is important to sustain current control efforts.

### Background

Onchocerciasis, or river blindness, is caused by infection with the filarial parasite *Onchocerca volvulus*. The parasite is transmitted by *Simulium* species (blackflies) that

breed in fast flowing streams [1,2]. Until recently the blindness and skin pathology caused by heavy infections, constituted a major public health problem in many parts of tropical Africa, Yemen, and Latin America. This con-

sideration led to the establishment of the Onchocerciasis Control Programme (OCP) [3] in West Africa, the Onchocerciasis Elimination Program in the Americas (OEPA) [4], and the African Program for Onchocerciasis Control (APOC) [5,6]. All three programmes have come to rely on the regular (OEPA semi-annually, OCP both annually and semi-annually, and APOC annually) distribution of ivermectin (Mectizan®) to lower the microfilarial load in affected individuals and thereby reduce transmission and mitigate the clinical manifestations of the infection [7]. In addition, since 1975, OCP has made intensive use of vector control by means of aerial larviciding. This has led to the virtual elimination of the parasite from many formerly endemic areas. However, as the OCP will come to an end in 2002, potential recrudescence of the infection, resulting from residual foci or immigration of infected humans and flies, remains a serious threat unless total elimination can be achieved [8]. In Africa, after the cessation of larviciding, control of the infection will rely on decentralized annual ivermectin distribution, which has been made available by Merck and Co. for as long as it will be needed. This has several disadvantages. First, in view of imperfect geographical and therapeutic coverage, and density dependence in the microfilarial uptake by flies [9,10], low level transmission may continue. Second, resistance to ivermectin might develop and spread [11], as it already has in some nematode parasites of veterinary importance [12–15]. Third, in man, the average life-span of adult worms is approximately 10 years, and while repeated treatments of ivermectin seem to have some permanent effect on the fertility of adult worms, this effect manifests itself only slowly after years of treatment [16].

Unfortunately, the number of safe effective alternative treatments is limited. Diethylcarbamazine, also a microfilaricide, causes severe side effects in onchocerciasis [17]. Suramin, the only currently available highly effective microfilaricide has even more serious side effects [18]. Large scale nodulectomy, which has been attempted in Latin America, is impractical and will never succeed in eliminating all adult worms [19,20].

Some success was obtained with amocarzine, although its microfilaricidal properties were not optimal [21]. Several other compounds are currently under consideration. One of these is doxycycline which following long-term treatment was shown to sterilize adult worms in treated humans, an effect that was correlated with the disappearance of the filarial endosymbiont (*Wolbachia* spp) [22,23]. Another promising drug, widely used in veterinary practice, is moxidectin [24,25]. When used as a single dose it either kills or sterilizes the adult worm depending on the animal model and parasite used. The half-life of this drug in animals is approximately 10 times

that of ivermectin, thereby reducing the probability of successful re-infection. However, the effect of this compound in humans remains to be evaluated.

The advantages of microfilaricidal drugs are obvious. With a 100% effective microfilaricide and 100% coverage, elimination could be achieved almost instantaneously. By contrast, with ivermectin, even with 100% coverage – impossible under current exclusion criteria – elimination of the infection from the community would take over a decade.

Even if not all adult worms were killed due to lower drug efficacy or incomplete coverage, a microfilaricide would still be more effective than ivermectin alone.

Taking in consideration the above issues we will address, by using the microsimulation ONCHOSIM model, the possible effects of incorporating a microfilaricidal drug on the control of *O. volvulus* and provide suggestions on how it should be best used.

## Methods

Both the life cycle of the parasite and the effects of an intervention are highly complex. While mathematical models can still be formulated explicitly, model equations are impossible to solve analytically [26–28].

Stochastic microsimulation was therefore used as a numerical technique to explore the potential of microfilaricides. The ONCHOSIM model and computer program, developed by Plaisier *et al* [29,30] was adapted to incorporate the effect of such a microfilaricide. We optimistically assumed that a single dose of the drug (or drug combination) under consideration would kill or sterilize 95% of all adult worms. We further assumed that it would have the same effects as ivermectin on the remaining worms. This could be achieved, if necessary, by combining the microfilaricide with ivermectin. We did not make any assumption about a protective prophylactic effect on re-infection. Parameters, such as the parasite uptake curve, validated to be appropriate for use in areas where the savannah type (blinding) vector-parasite complex dominates, were available as default settings for this programme [30]. In all cases a 10-year programme of annual microfilariciding was considered. While longer periods may have higher success rates, in practice it may be unrealistic to expect that control programmes can be sustained uninterruptedly for many decades. The outcome of interest is the probability that this 10 years programme would lead to elimination of the parasite from a closed community (village) of approximately 400 people.

Three scenarios were considered for simulation.

1. A scenario in which the introduction of the macrofilaricide follows a period of 12 years of intensive control with larviciding (achieving a conservative 65% reduction in biting rates) and ivermectin distribution. Prevalence and transmission have been reduced to a very low level. This pattern is characteristic of many areas covered by OCP. The impact of the macrofilaricide is contrasted with a continued distribution of ivermectin (for 10 years), both in the absence of continued larviciding (i.e. the situation as it will prevail in the OCP countries after the OCP has been phased out).

2. A scenario in which control has been limited to 5 years of annual ivermectin distribution. By the time macrofilaricides become available this will be characteristic of many areas covered by the African Programme for Onchocerciasis Control (APOC). Following these 5 years of ivermectin distribution continued ivermectin distribution for 10 years is compared to its replacement with the macrofilaricide (or a combination of the two drugs).

3. A scenario in which there has not been any control measures for many years. This is typical for areas not covered by either OCP or APOC. This scenario also characterizes areas, such as parts of the north of Sierra Leone, in which the programme has been suspended for many years. The macrofilaricide is compared to the introduction of ivermectin distribution.

To adjust the level of endemicity we used the entomological parameter "biting rate". At Asubende, a highly endemic area with a community microfilarial load (CMFL) [31] of approximately 60–70 mf per skin snip, a mean

monthly biting rate of 2400 *s. damnosum* bites for an adult human male has been observed. For each of these scenarios above we considered sub-scenarios with biting rates equal to the Asubende level, equal to 50% above (i.e. a monthly biting rate of 3600) and equal to 50% below (i.e. a biting rate of 1200) this level. Biting rates for other types of individuals (women, children) were assumed proportional to the biting rate in adult males. For all scenarios we only considered mass treatment once annually. Another parameter that we varied was the coverage. Both a "low" coverage of 50% and a high coverage of 75% of the total population were considered. Each configuration was simulated a 100 times. In all cases we assumed that groups not eligible for ivermectin treatment (pregnant women, children under 5 years of age) were neither eligible for macrofilaricide treatment. Compliance was not considered to be fully random, but to depend on an individual's propensity to adhere to treatment [32]. This implies that individuals with a low propensity to comply may act as a reservoir for the parasite and this scenario is thus more pessimistic (especially for macrofilaricides) than completely random adherence. We ignored all forms of drug resistance. We did not consider the effects of immigration of infected individuals or the influx of infected flies. This means that conclusions regarding elimination of infection are only valid when interventions are targeted at sufficiently large areas simultaneously and the probability of elimination in individual communities is high.

**Results**

The results are shown in Table 1.

**Table 1: Simulation results, using ONCHOSIM. Cells are based on 100 simulations each. Each cell shows number of eliminations obtained with a macrofilaricide/number of eliminations obtained with ivermectin.**

Coverage (percentage of individuals actual getting treatment during mass treatment)	Monthly Biting Rate	Number of successful eliminations macrofilaricide/ivermectin per 100 simulations		
		Scenario 1 ('OCP')	Scenario2 ('APOC')	Scenario3 (no previous intervention)
50%	1200	100/100	97/42	64/0
50%	2400	78/23	0/0	0/0
50%	3600	1/0	0/0	0/0
75%	1200	100/100	100/100	100/97
75%	2400	100/100	98/0	68/0
75%	3600	100/98	28/0	9/0

## Discussion

Low levels of infection and transmission of onchocerciasis, as indicated by a low CMFL, have little public health impact, and mild infections can go almost unnoticed. An intervention programme that would succeed in keeping epidemiological indices at low levels would therefore have a public health impact similar to actual elimination of the parasite. In the absence of the development of resistance, annual ivermectin distribution with a reasonably high coverage is probably totally adequate for this. Even under conditions of continued high transmission, ivermectin based control programs could prevent or mitigate most of the morbidity of onchocerciasis infections. Yet, we have chosen elimination as our target. The reason for this is that in the absence of elimination, control measures would have to be sustained and should retain their effectiveness. Failing these conditions, e.g. due to the development of resistance, recrudescence to pre-intervention levels may only be a matter of time.

We explored the potential of macrofilaricides to bring about elimination. Coverage is key, as non-compliant individuals may act as reservoirs for the infection and thereby perpetuate transmission. Obviously, macrofilariciding if applied to 100% of the population – currently unattainable – must quickly lead to elimination of the parasite. Still, if only few individuals escape treatment, the reservoir of infection will ultimately be depleted by the natural mortality of the parasite, assuming that immigration of new L3 larvae has been interrupted. Whether a specific coverage level under specific circumstances would achieve elimination can best be theoretically explored using microsimulation. In this study, such simulations were used to explore whether elimination would be feasible within 10 years. We made several assumptions that we believe reflect the limitations that actual control programs could encounter. First, similar to ivermectin, children under 5 were assumed to be excluded from treatment. Second, we assumed that treatment adherence was imperfect and that some individuals have a greater propensity to escape treatment than others.

We considered several scenarios. Our main objective was twofold, viz. estimating the 'absolute' probability of elimination of the parasite from the community, and to compare this probability to that of (continued) use of ivermectin alone. In all cases we found that a macrofilaricide had a substantially higher potential for achieving elimination than ivermectin. Yet, even with a macrofilaricide, elimination would rarely be achieved within 10 years when treatment coverage is low and/or biting rates are high. Control efforts prior to the introduction of the macrofilaricide also appeared to be important: in "OCP" areas, with highly favourable epidemiological indices at the outset of macrofilariciding, continued use of iver-

mectin alone would also often lead to elimination. As we only evaluated the success rates of entire programmes (i.e. including all preceding control measures), in some instances elimination might have been achieved even in the absence of those extra 10 years of treatment. Outside "OCP" areas (scenarios 2 and 3) elimination would never be achieved by ivermectin alone within 10 (additional) years, unless biting rates were low. By contrast, even under difficult conditions of high biting rates or low coverage, macrofilaricide based programmes would occasionally be successful within 10 years. If so, provided programmes are continued for a sufficiently longer period, ultimate success would be likely.

We wish to stress that our conclusions are based on microsimulations and are therefore contingent upon the validity of the model and the assumed properties of the drug. Real macrofilaricides may have properties that differ from those assumed in the model. For example, the drug may prevent re-infection for some time following treatment (thereby enhancing its effect) or it may sterilize female worms but be ineffective against male adult worms (thereby reducing its effect). Arguably, even the most effective antihelminths (e.g. albendazole against ascariasis) barely have our assumed 95% killing rate. Whenever a macrofilariciding drug becomes available for human use, extensive simulations should be carried out to explore its potential. Nevertheless, only community trials can demonstrate whether modelling results can be replicated in the field.

## Conclusions

Macrofilaricides have a substantially higher potential for achieving onchocerciasis elimination than ivermectin, but high coverage levels are still key. When these drugs become available for human use, onchocerciasis elimination strategies should be reconsidered. In view of the impact of control efforts preceding the introduction of macrofilaricides on the success of elimination, it is important to sustain current control efforts.

## Competing interests

None declared.

## References

1. World Health Organization: **Onchocerciasis and its Control**, WHO Technical Report Services, N° 852 1995
2. Duke BOL: **Human onchocerciasis – An overview of the disease**. *Acta Leiden* 1990, **59**:9-24
3. Molyneux DH: **Onchocerciasis Control in West Africa: current status and future of the Onchocerciasis Control Programme**. *Parasit Today* 1995, **11**:399-401
4. Blanks J, Richards F, Beltran F, Collins R, Alvarez E, Zea Flores G, Bauler B, Cedillos R, Heisler M, Brandling-Bennett D, Baldwin W, Bayona M, Klein R, Jacox M: **The Onchocerciasis Elimination Program for the Americas: a history of partnership**. *Rev Panam Salud Publica* 1998 Jun, **3(6)**:367-74
5. Remme JHF: **The African Programme for Onchocerciasis Control: preparing to launch**. *Parasit Today* 1995, **11**:403-406

6. World Health Organization: *25 years OCP: 1974-1999*. WHO: Geneva, 1999
7. Goa KL, McTavish D, Clissold SP: **Ivermectin: A review of its antilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.** *Drugs* 1991, **42**:640-658
8. Plaisier AP, Van Oortmarssen GJ, Remme J, Alley ES, Habbema JDF: **The risks and dynamics of onchocerciasis recrudescence after cessation of vector control.** *Bull Wild Hlth Org* 1991b, **69**:169-178
9. Dietz K: **Density-dependence in parasite transmission dynamics.** *Parasit Today* 1988, **4**:91-97
10. Basanez MG, Remme JHF, Alley ES, et al: **Density dependent processes in the transmission of human onchocerciasis: relationship between the number of microfilariae ingested and successful larval development in the simuliid vector.** *Parasitology* 1995, **110**:409-427
11. Boussinesq M, Gardon J: **La résistance de *Oncocerca volvulus* à l'ivermectine: une éventualité à considérer.** *Ann Inst. Pasteur*, 1999, **10**,1:81-91
12. Dent JA, Smith MM, Vassiliadis DK, Avery L: **The genetics of ivermectin resistance in *Caenorhabditis elegans*.** *Proc Natl Acad Sci USA* 2000, **97**(6):2674-9
13. Burkhart CN: **Ivermectin: an assessment of its pharmacology, microbiology and safety.** *Vet Hum Toxicol* 2000, **42**(1):30-5
14. Young KE, Garza V, Snowden K, Dobson RJ, Powell D, Craig TM: **Parasite diversity and anthelmintic resistance in two herds of horses.** *Vet Parasitol* 1999, **85**(2-3):205-214
15. Gopal RM, Pomroy WE, West DM: **Resistance of field isolates of *Trichostrongylus colubriformis* and *Ostertagia circumcincta* to ivermectin.** *Int J Parasitol* 1999, **29**(5):781-786
16. Plaisier AP, Alley ES, et al: **"Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa."** *J Infect Dis* 1995, **172**(1):204-210
17. Francis H, Awadzi K, Ottesen EA: **The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity.** *Am J Trop Med Hyg* 1985, **34**(3):529-536
18. Thylefors B, Rolland A: **The risk of optic atrophy following suramin treatment of ocular onchocerciasis.** *Bull World Health Organ* 1979, **57**(3):479-480
19. Guderian RH, Anselmi M, Espinel M, Mancero T, Rivadeneira G, Proano R, Calvopina HM, Vieira JC, Cooper PJ: **Successful control of onchocerciasis with community-based ivermectin distribution in the Rio Santiago focus in Ecuador.** *Trop Med Int Health* 1997, **2**(10):982-988
20. Guderian RH: **Effects of nodulectomy in onchocerciasis in Ecuador.** *Trop Med Parasitol* 1988, **39** Suppl 4:356-357
21. Poltera AA, Zea-Flores G, Guderian R, Beltranena F, Proana R, Moran M, Zak F, Striebel HP: **Onchocercicidal effects of amocarzine (CGP 6140) in Latin America.** *Lancet* 1991, **337**(8741):583-584
22. Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fleischer B, Buttner DW: **Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis.** *Lancet* 2000 Apr 8, **355**(9211):1242-1243
23. Langworthy NG, Renz A, Mackenstedt U, Henkle-Duhrsen K, de Bronsvort MB, Tanya VN, Donnelly MJ, Trees AJ: **Macrofilaricidal activity against the filarial nematode *Onchocerca ochengi*: elimination of *Wolbachia* precedes worm death and suggests a dependent relationship.** *Proc R Soc Lond B Biol Sci* 2000, **267**:1063-1069
24. Trees AJ, Graham SP, Renz A, Bianco AE, Tanya V: ***Onchocerca ochengi* infections in cattle as a model for human onchocerciasis: recent developments.** *Parasitology* 2000, **120** Suppl:SI33-142
25. Tagboto SK, Townson S: ***Onchocerca volvulus* and *O. ienalis*: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo.** *Ann Trop Med Parasitol* 1996 Oct, **90**(5):497-505
26. Basañez M, Ricardez-Esquinca J: **Models for the population biology and control of human onchocerciasis.** *Trends Parasitol* 2001 Sep, **17**(9):430-8
27. Anderson RM, May RM: **Infectious Diseases of Humans: Dynamics and Control.** Oxford: Oxford University Press, 1992
28. Diekmann O, Heesterbeek JAP: **Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation.** New York: Wiley, 2000
29. Plaisier AP, van Oortmarssen GJ, Habbema JD, Remme J, Alley ES: **ONCHOSIM: a model and computer simulation program for the transmission and control of onchocerciasis.** *Comput Methods Programs Biomed* 1990, **31**(1):43-56
30. Habbema JD, Van Oortmarssen GJ: **The ONCHOSIM model and its use in decision support for river blindness control.** In: *Isham V, Medley GF [eds]. Epidemic models: their structure and relation to data.* Cambridge, Cambridge University Press, 1996
31. Remme JHF, Ba O, Dadzie KY, Karam M: **A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River Basin area.** *Bulletin of the World Health Organization*, 1986, **64**(5):667-681
32. Habbema JDF, Alley ES, Plaisier AP, Van Oortmarssen GJ, Remme JHF: **Epidemiological modelling for onchocerciasis control.** *Parasitology today* 1992, **48**:271-284

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedCentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)